Is N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide? Is N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide safe for nursing mother and child? Does N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide extracts into breast milk? Does N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide has any long term or short term side effects on infants? Can N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide influence milk supply or can N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide decrease milk supply in lactating mothers?
N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide lactation summary
- DrLact safety Score for N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide usage in lactation
Used for treatment of insomnia. It is excreted in non-significant clinical amount into breast milk. Foods with high fat content may delay absorption by the gut. A low oral bioavailability decreases the pass of it from the mother's milk to the infant's plasma, except in prematures or in the early neonatal period, when a higher intestinal absorption may occur. Not commercially available in Spain
Answer by DrLact: About N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide usage in lactation
Because of the low levels of N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide in breastmilk and its short half-life, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. No special precautions are required.
Alternate Drugs
Triazolam(Low Risk)
Lormetazepam(Safe)
Temazepam(Low Risk)
Ketamine(Low Risk)
Quazepam(Unsafe)
Estazolam(Low Risk)
Flurazepam(Unsafe)
Phenobarbital(Low Risk)
Meprobamate(Low Risk)
Oxazepam(Safe)
Butalbital(Low Risk)
Midazolam(Safe)
Butabarbital(Low Risk)
Lorazepam(Safe)
Pentobarbital(Low Risk)
Eszopiclone(Low Risk)
Secobarbital(Low Risk)
Diazepam(Low Risk)
Clorazepate(Low Risk)
Propofol(Safe)
Alprazolam(Low Risk)
Chlordiazepoxide(Low Risk)
Sodium Oxybate(Low Risk)
Chloral Hydrate(Low Risk)
Zolpidem(Safe)
Nitrazepam(Low Risk)
Zaleplon(Safe)
Flunitrazepam(Unsafe)